• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 8
  3. Author

Online ISSN: 2515-8260

Volume9, Issue8

DERMATOFIBROSARCOMA PROTUBERANS – CASE REPORT

    Dr. Trupti Tonape, Dr. Rodda Suma, Dr. Priyanka Subramanyam .

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 8, Pages 3260-3263

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a rare type of skin cancer which is locally aggressive. Slow growing fibrohistiocytic neoplasm considered of low to medium malignancy.  It starts in connective tissue cells in the middle layer of skin (dermis) and poorly circumscribed usually involves dermis and subcutis. DFSP might look like a pimple or feel like a rough patch of skin at first. It is a rare tumor with an incidence rate of 0.8 to 4.5 cases per million persons per year (2,3,4,5,6). Represents less than 5% of all soft tissue sarcomas. DFSP occurs most often in adults in 3rd to 5th decades of life but has been reported in all age groups, including congenital presentation. Tumour is usually positive for CD-34. Treatment consists of surgical resection with negative margins. In cases where surgical resection with negative margins is not possible, radiation and systemic therapy with tyrosine kinase inhibitors, such as imatinib mesylate, has been shown to be effective. Regular follow up of the patients is essential.
Keywords:
    Dermatofibrosarcoma protuberans fibrohistiocytic neoplasm surgical resection negative margins imatinib mesylate
  • PDF (202 K)
  • XML
(2023). DERMATOFIBROSARCOMA PROTUBERANS – CASE REPORT. European Journal of Molecular & Clinical Medicine, 9(8), 3260-3263.
Dr. Trupti Tonape, Dr. Rodda Suma, Dr. Priyanka Subramanyam .. "DERMATOFIBROSARCOMA PROTUBERANS – CASE REPORT". European Journal of Molecular & Clinical Medicine, 9, 8, 2023, 3260-3263.
(2023). 'DERMATOFIBROSARCOMA PROTUBERANS – CASE REPORT', European Journal of Molecular & Clinical Medicine, 9(8), pp. 3260-3263.
DERMATOFIBROSARCOMA PROTUBERANS – CASE REPORT. European Journal of Molecular & Clinical Medicine, 2023; 9(8): 3260-3263.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 4
  • PDF Download: 12
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus